# Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

- Link: https://www.thailand-business-news.com/pr-news/ribo-and-madrigal-reach-first-major-milestone-in-advancing-novel-sirna-therapies-for-mash
- Published: 2026-07-02T08:29:00+07:00
- Author: PR Newswire

|   |

SUZHOU, China and MÖLNDAL, Sweden, July 2, 2026 /PRNewswire/ — Suzhou Ribo Life 
Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively
referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal,
NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination
milestone within their siRNA partnership. This milestone is the result of efficient
collaboration and will be followed by immediate initiation of IND-enabling studies
to support planned clinical studies.

This partnership fully underscores Ribo’s and Madrigal’s joint commitment to advancing
cutting-edge RNA therapeutics for liver diseases, with a primary focus on metabolic
dysfunction-associated steatohepatitis (MASH), a field with tremendous unmet medical
need. The collaboration covers multiple preclinical assets and further broadens 
the potential liver-directed therapeutic landscape for MASH.

_"We are delighted to achieve the first key milestone in our joint MASH program 
with Madrigal in just a few months. Madrigal has established a market leading presence
and profound clinical expertise in the MASH field, while Ribo possesses world-class
capabilities in siRNA drug discovery and delivery technology._  _Our complementary
strengths have driven the rapid progress of this project. Both parties are dedicated
to accelerating the development of our novel siRNA candidate for MASH. We look forward
to advancing this collaborative program together and bringing promising new therapeutic
options to patients worldwide living with MASH,"_ said Li-Ming Gan, co-CEO & Global
R&D President of Ribo.

**About Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB**
Suzhou
Ribo Life Science Co. Ltd. (Ribo, 06938.HK) is an innovative clinical stage R&D 
company devoted to the development of nucleic acid drugs and related products based
on the RNA interference (RNAi) technology. With its innovative R&D capabilities 
with vertically integrated technological platforms, Ribo has built a strong product
pipeline, aiming to make contribution to the treatment of serious diseases with 
unmet medical needs.As a subsidiary of Suzhou Ribo Life Science, Ribocure Pharmaceuticals
AB (Ribocure) is dedicated to globalized development of life-saving oligonucleotide
therapies, with focus on development of assets and pipeline as well as new target
ideas and on building innovative capacities to conduct clinical trials and developing
siRNA drugs to address real unmet medical needs globally. For more information, 
please visit [www.ribolia.com](https://www.ribolia.com/) and [www.ribocure.com](https://www.ribocure.com/).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH ](http://www.prnasia.com/story/archive/4996894_AE96894_0?rand=184833)